Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1683494 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL11267217 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL10932529 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL14485494 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL5697033 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL4362914 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL9031506 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL9487974 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL6388831 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL5157618 | 0.90 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723701-B1 | METHOD OF MAKING PHOSPHONO-PHOSPHATE CONTAINING COMPOUNDS | PROCTER & GAMBLE (US) | 2025-08-06 | — | — | EP | claimed |
| CN-111372553-B | Process for preparing phosphonyl-phosphate containing compounds | 宝洁公司 | 2023-08-25 | — | — | CN | claimed |
| EP-3723701-A1 | METHOD OF MAKING PHOSPHONO-PHOSPHATE CONTAINING COMPOUNDS | The Procter & Gamble Company (US) | 2020-10-21 | — | — | EP | claimed |
| US-10752646-B2 | Method of making phosphono-phosphate containing compounds | THE PROCTER & GAMBLE COMPANY (US) | 2020-08-25 | — | — | US | claimed |
| CN-111372553-A | Process for preparing phosphono-phosphate-containing compounds | 宝洁公司 | 2020-07-03 | — | — | CN | claimed |
| WO-2019118418-A1 | METHOD OF MAKING PHOSPHONO-PHOSPHATE CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-06-20 | — | — | WO | claimed |
| US-20190177348-A1 | Method Of Making Phosphono-Phosphate Containing Compounds | THE PROCTER & GAMBLE COMPANY | 2019-06-13 | — | — | US | claimed |
| EP-3723701-B1 | METHOD OF MAKING PHOSPHONO-PHOSPHATE CONTAINING COMPOUNDS | PROCTER & GAMBLE (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-111372553-B | Process for preparing phosphonyl-phosphate containing compounds | 宝洁公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-3723701-A1 | METHOD OF MAKING PHOSPHONO-PHOSPHATE CONTAINING COMPOUNDS | The Procter & Gamble Company (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10752646-B2 | Method of making phosphono-phosphate containing compounds | THE PROCTER & GAMBLE COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| CN-111372553-A | Process for preparing phosphono-phosphate-containing compounds | 宝洁公司 | 2020-07-03 | — | — | CN | disclosed |
| WO-2019118418-A1 | METHOD OF MAKING PHOSPHONO-PHOSPHATE CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20070184035-A1 | ARTIFICIAL STABILIZED COMPOSITION OF CALCIUM PHOSPHATE PHASES PARTICULARLY ADAPTED FOR SUPPORTING BONE CELL ACTIVITY | MILLENIUM BIOLOGIX, INC. | 2007-08-09 | — | — | US | disclosed |
| EP-0847376-B1 | AN ARTIFICIAL STABILIZED COMPOSITION OF CALCIUM PHOSPHATE PHASES PARTICULARLY ADAPTED FOR SUPPORTING BONE CELL ACTIVITY | MILLENIUM BIOLOGIX INC (CA) | 2005-02-23 | — | — | EP | disclosed |
| EP-0666902-B1 | ASSESSMENT OF BONE CELL ACTIVITY | MILLENIUM BIOLOGIX INC (CA) | 2000-01-12 | — | — | EP | disclosed |
| US-5849569-A | Assessment of bone cell activity | MILLENIUM BIOLOGIX, INC. (CA) | 1998-12-15 | — | — | US | disclosed |
| EP-0847376-A1 | AN ARTIFICIAL STABILIZED COMPOSITION OF CALCIUM PHOSPHATE PHASES PARTICULARLY ADAPTED FOR SUPPORTING BONE CELL ACTIVITY | MILLENIUM BIOLOGIX INC. (CA) | 1998-06-17 | — | — | EP | disclosed |
| US-5766669-A | Sintering process for producing thin films of calcium phosphate entities | MILLENIUM BIOLOGIX INC. (CA) | 1998-06-16 | — | — | US | disclosed |
| WO-1997009286-A1 | AN ARTIFICIAL STABILIZED COMPOSITION OF CALCIUM PHOSPHATE PHASES PARTICULARLY ADAPTED FOR SUPPORTING BONE CELL ACTIVITY | MILLENIUM BIOLOGIX, INC. (CA) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177348-A1 | Method Of Making Phosphono-Phosphate Containing Compounds | PHOSPHO1, PPA1, PPIP5K2 | SLC34A1 129/4885LMNA 3193/4885KDM4E 4755/4885 |
| US-10752646-B2 | Method of making phosphono-phosphate containing compounds | PHOSPHO1, PPA1, PPIP5K2 | SLC34A1 129/4885LMNA 3193/4885KDM4E 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.